Review: SABCS 2010 - Current treatment options for patients with breast cancer;Review: SABCS 2010 - Aktuelle Therapie der Patientin mit einem Mammakarzinom

Geburtshilfe und Frauenheilkunde

Volumn 71, Issue 4, 2011, Pages 260-276

  Fehm, T ^a   Janni, W ^b   Kummel S ^c   Luftner D ^d   Lux, M P ^e   Schutz F ^f   Fasching, P A ^e,g  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^c KLINIKEN ESSEN MITTE   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^f UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AZURE; circulating tumorcells (CTC); GeparQuinto; NeoALTTO; TAMRAD

Indexed keywords

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER THERAPY; CLINICAL PRACTICE; DECISION MAKING; HEREDITY; HUMAN; REVIEW;

EID: 79955820585     PISSN: 00165751     EISSN: 14388804     Source Type: Journal    
DOI: 10.1055/s-0030-1271020     Document Type: Review

References (55)

1. Rae J M., Drury S, Hayes D F. et al. Lack of correlation between gene variants in Tamoxifen metabolizing enzymes with primary endpoints in the ATAC trial. SABCS 2010 Abstract S1-7
2. Leyland-Jones B, Regan M M., Bouzyk M et al. Outcome according to CYP2D6 genotype among postmenopausal women with endocrine-responsive early invasive breast cancer randomized in the BIG 1-98 trial. SABCS 2010 Abstract S1-8
3. Schroth W, Goetz M P., Hamann U et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 2009 302 1429-1436
4. Ingle J N., Liu M, Wickerham D L. et al. Genome-wide associations of breast events and functional genomic studies in high-risk women receiving tamoxifen or raloxifene on NSABP P1 and P2 prevention trials. A pharmacogenomics research network-RIKEN-NSABP collaboration. SABCS 2010 Abstract PD05-02
5. Bartlett J, Brookes C, van de Velde C et al. Final results of a prospectively planned biomarker analysis: HER-13 as predictive markers of benefit from early treatment with aromatase inhibitors versus tamoxifen in the TEAM pathology sub-study. Cancer Res 2010 70 80 s (S2-4)
6. Dunbier A K., Ghazoui Z, Anderson H et al. Molecular profiling of aromatase inhibitor-treated postmenopausal breast tumours identifies determinants of response. Cancer Res 2010 70 80 s (S2-5)
7. Lindstroem L, Karlsson E, Wilking U et al. Discordance in hormone receptor and HER-2 status in breast cancer during tumor progression. Cancer Res 2010 70 83 s (S3-5)
8. Shulman L N., Cirrincione C, Berry D A. et al. Four vs. 6 cycles of doxorubicin and cyclophosphamide (AC) or paclitaxel (T) as adjuvant therapy for breast cancer in women with 0 3 positive axillary nodes: CALGB 40101 A 2×2 factorial phase III trial: first results comparing 4 vs. 6 cycles of therapy. SABCS 2010 Abstract S6-3
9. O'Shaughnessy J, Miles D, Vukelja S et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002 20 2812-2823 (Pubitemid 34651510)
10. Kurosumi M, Tabei T, Suemasu K et al. Enhancement of immunohistochemical reactivity for thymidine phosphorylase in breast carcinoma cells after administration of docetaxel as a neoadjuvant chemotherapy in advanced breast cancer patients. Oncol Rep 2000 7 945-948
11. Fujimoto-Ouchi K, Tanaka Y, Tominaga T. Schedule dependency of antitumor activity in combination therapy with capecitabine/5-deoxy-5-fluorouridine and docetaxel in breast cancer models. Clin Cancer Res 2001 7 1079-1086 (Pubitemid 32708748)
12. Endo M, Shinbori N, Fukase Y et al. Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5-deoxy-5- fluorouridine by cyclophosphamide in mammary tumor models. Int J Cancer 1999 83 127-134 (Pubitemid 29409488)
13. Sawada N, Ishikawa T, Fukase Y et al. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 1998 4 1013-1019 (Pubitemid 28183404)
14. Joensuu H, Kellokumpu-Lehtinen P-L, Huovinen R et al. FinXX final 5-year analysis: Results of the randomised, openlabel, phase II trial in medium-to-high risk early breast cancer. SABCS 2010 Abstract S4-1
15. Poole C, Barrios C, O'Shaughnessy J et al. Ongoing evaluation of capecitabine-based therapy in early breast cancer (EBC). SABCS 2010 Abstract P5-10-11
16. Joensuu H, Kellokumpu-Lehtinen P L., Huovinen R et al. Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial. Lancet Oncol 2009 10 1145-1151 Epub 2009 Nov 10
17. Lluch A, Gomez H, Ruiz-Borrego M et al. First safety data from a randomised phase III (CIBOMA 2004-01/GEICAM 2003-11) trial assessing adjuvant capecitabine maintenance therapy after standard chemotherapy for triple-negative early breast cancer. SABCS 2010 Abstract P5-10-15
18. O'Shaughnessy J, Devchand P, Stokoe C et al. First efficacy results of a randomized, open-label, phase II study of adjuvant doxorubicin plus cyclophosphamide followed by docetaxel with or without capecitabine in high-risk early breast cancer. SABCS 2010 Abstract S4-2
19. von Minckwitz G, Untch M, Nüesch E et al. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat 2011 125 145-156 Epub 2010 Nov 3
20. Recht A, Come S E., Henderson I C. et al. The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N Engl J Med 1996 334 1356-1361 (Pubitemid 26152714)
21. Bellon J R., Come S E., Gelman R S. et al. Sequencing of chemotherapy and radiation therapy in early-stage breast cancer: updated results of a prospective randomized trial. J Clin Oncol 2005 23 1934-1940 (Pubitemid 46211372)
22. Fernando I N., Bowden S J., Buckley L at al. SECRAB: The optimal sequencing of adjuvant chemotherapy (CT) and radiotherapy (RT) in early breast cancer (EBC), results of a UK multicentre prospective randomised trial. SABCS 2010 Abstract S4-4
23. Fernando I N., Bowden S J., Buckley L et al. Acute and late toxicity results from the SECRAB trial: The optimal sequencing of adjuvant chemotherapy (CT) and radiotherapy (RT) in early breast cancer (EBC). SABCS 2010 Abstract P4-11-05
24. Coleman R E., Thorpe H C., Cameron D et al, AZURE (BIG 01/01) Investigators. Adjuvant treatment with zoledronic acid in stage II/II breast cancer. The AZURE trial (BIG 01/04). SABCS 2010 Abstract S4-5
25. Sverrisdottir A, Johansson H, Johansson U et al. Interaction between goserelin and tamoxifen in a controlled clinical trial of adjuvant endocrine therapy in premenopausal breast cancer. SABCS 2010 Abstract S1-5
26. Goss P E., Ingle J N., Chapman J-A W. et al. MA.27: A randomized phase II trial of exemestane versus anastrozole in postmenopausal women with hormone receptor positive primary breast cancer. SABCS 2010 Abstract S1-1
27. Gianni L, Pienkowski T, Im Y-H et al. Neoadjuvant pertuzumab (P) and trastuzumab (H): antitumor and safety analysis of a randomized phase II study (NeoSphere). Cancer Res 2010 70 (24 Suppl.) 82s
28. Baselga J, Bradbury I, Eidtmann H et al. First results of the NeoALTTO trial (BIG 01-06/EGF 106903): a phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER-2-positive primary breast cancer. Cancer Res 2010 70 (24 Suppl.) 82s
29. Untch M, Loibl S, Bischoff J et al. Lapatinib vs. trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy: primary efficacy endpoint analysis of the GEPARQUINTO STUDY (GBG 44). SABCS 2010 Abstract S3-1
30. Bischoff J, Ignatov A. The role of targeted agents in the treatment of metastatic breast cancer. Breast Care (Basel) 2010 5 134-141 Epub 2010 Jun 16
31. von Minckwitz G, Eidtmann H, Rezai M et al. Neoadjuvant chemotherapy with or without Bevacizumab: Primary efficacy endpoint analysis of the GEPARQUINTO Study (GBG 44). SABCS 2010 Abstract S4-6
32. Loibl S, Amant F, Kaufmann M et al. 313 patients with breast cancer during pregnancy results from a prospective and retrospective registry (GBG-20/BIG 02-03). SABCS 2010 Abstract S6-2
33. Bachelot T, Bourgier C, Cropet C et al. TAMRAD: a GINECO randomized phase II trial of everolimus in combination with tamoxifen versus tamoxifen alone in patients (pts) with hormone-receptor positive, HER-2 negative metastatic breast cancer (MBC) with prior exposure to aromatase inhibitors (AI). SABCS 2010 Abstract S1-6
34. Kaufman P A., Ferrero J M., Bourgeois H et al. A randomized, placebo-controlled, phase 2 study of AMG 479 with exemestane (E) or fulvestrant (F) in postmenopausal women with hormone-receptor positive (HR+) locally advanced (LA) or metastatic (M) breast cancer (BC). SABCS 2010 Abstract S1-4
35. Di Leo A, Jerusalem G, Petruzelka L et al. Results of the CONFIRM phase III trial comparing fulvestrant 250mg with fulvestrant 500mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 2010 28 4594-4600
36. Robertson J F. R., Lindemann J P. O., Llombart-Cussac A et al. A comparison of fulvestrant 500 mg with anastrozole as first-line treatment for advanced breast cancer: follow-up analysis from the FIRST study. SABCS 2010 Abstract S1-3
37. Rack B K., Schindlbeck C, Andergassen U et al. Use of circulating tumor cells (CTC) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy to predict risk for relapse: The SUCCESS trial. J Clin Oncol 2010 28 15s (Suppl., Abstr. 1003)
38. Giordano A, Giuliano M, Hsu L et al. Prognostic value of circulating tumor cells (CTC) in metastatic breast cancer (MBC): correlation with immunohistochemically defined molecular subtypes and metastatic disease sites. J Clin Oncol 2010 28 15s (Suppl., Abstr. 1000)
39. Pierga J-Y, Bachelot T, Delaloge S et al. High independent prognostic and predictive value of circulating tumor cells in a large prospective multicenter trial including serum tumor markers in first line chemotherapy metastatic breast patients. SABCS 2010 Abstract S6-6
40. Aktas B, Tewes M, Kimmig R et al. Molecular profiling of circulating tumor cells in blood of metastatic breast cancer patients indicates therapy response and provides information on epithelial mesenchymal transition and tumor stem cell metabolism. SABCS 2010 Abstract PD04-04
41. Rack B, Schindlbeck C, Andergassen U et al. Prognostic relevance of circulating tumor cells in the peripheral blood of primary breast cancer patients. SABCS 2010 Abstract S6-5
42. Pierga J-Y, Bidard F-C, Petit T et al. Monitoring circulating tumor cells (CTC) and circulating endothelial cells (CEC) during neoadjuvant combination of trastuzumab and bevacizumab with chemotherapy in HER-2 overexpressing inflammatory breast cancer (IBC): an ancillary study of BEVERLY 2 multicenter phase II trial. SABCS 2010 Abstract PD04-07
43. Riethdorf S, Mueller V, Mauermann O et al. Changes in circulating tumor and endothelial cells in peripheral blood of patients treated in the neoadjuvant chemotherapy plus targeted treatment breast cancer study GeparQuinto. SABCS 2010 Abstract PD04-06
44. Spector N, Duke University Medical Center Durham, NC. Drug development targeting HER-2 beyond trastuzumab. Plenary lecture. SABCS 2010.
45. Blackwell K L., Burstein H J., Storniolo A M. et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010 28 1124-1130
46. Carey L A., University of North Carolina Chapel Hill, NC. Progress in advanced breast cancer. The year in review. SABCS 2010.
47. Bernow M, Wilking U, Bergh J et al. Re-testing of HER-2 status in recurring metastatic breast cancer is a clinically relevant and cost-effective strategy. Cancer Res 2010 70 (24 Suppl.) 157s-158s
48. Sledge jr. G W., Indiana University Simon Cancer Center Indianapolis, IN. What would Bill do? Channeling your inner McGuire. William McGuire memorial lecture. SABCS 2010.
49. Hershman D L., Neugut A I., Subar M et al. Association between prescription co-payment amount and compliance with adjuvant aromatase inhibitor therapy in women with early stage breast cancer. Cancer Res 2010 70 (24 Suppl.) 91s
50. Sehgal R, Lark C. A pharmaco-economic analysis of tamoxifen (T) vs. aromatase inhibitors (AI) in adjuvant treatment of postmenopausal (PoM) women (W) with hormone receptor positive (HRP) breast cancer (BC). Cancer Res 2010 70 (24 Suppl.) 157s
51. Hershman D L., Shao T, Kushi L H. et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 2011 126 529-537
52. Force R W., Pugmire B A., Culbertson V L. Taxanes in metastatic breast cancer: claims analysis of neutropenia, infections, and CSF costs. Cancer Res 2010 70 (24 Suppl.) 157s
53. Arpino G, Cammarota S, Ianniello G et al. Imaging tests in staging and surveillance of early breast cancer (EBC) changes in routine clinical practice and cost implications. Cancer Res 2010 70 (24 Suppl.) 158s
54. Chastek B, Gao S, O'Malley C et al. Health care costs incurred by post-menopausal women with hormone-positive breast cancer following the initial diagnosis of metastasis. Cancer Res 2010 70 (24 Suppl.) 156s
55. Baser O, Wei W, Henk H J. et al. Survival, health care cost and utilization of patients with triple negative breast cancer in a U.S. managed care setting. Cancer Res 2010 70 (24 Suppl.) 158s-159s